A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: Boehringer Ingelheim
A observational or N/A phase clinical study on Neoplasms, this trial is ongoing. The trial is conducted by Boehringer Ingelheim and has accumulated 46 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
46 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
-
Apr 16, 2026 — May 4, 2026 [daily]
Active Not Recruiting
Phase: PHASE1 → None
-
Mar 2026 — Apr 2026 [monthly]
Active Not Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
▶ Show 41 earlier versions
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Sep 2023 — Jan 2024 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of Part 1 of this study is to find the highest dose of a medicine called BI 765179 that people with solid tumors can tolerate when taken alone or together with a medicine called ezabenlimab. The goal of Part 2 is to find out whether BI 765179 in combination with a medicine called pembrolizumab helps people with advanced head and neck cancer. In Part 1, each participant is put into 1 of 2 groups. Participants get BI 765179 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. In Part 2, participants are also divided into 2 groups. 1 group gets a low dose of BI 765179 in combination with pembrolizumab and the other group gets a high dose of BI 765179 in combination with pembrolizumab. Participants receive the study treatment as infusions into a vein. BI 765179, ezabenlimab, and pembrolizumab are antibodies that may help the immune system fight cancer. In this study, BI 765179 is given to people for the first time. Participants can stay in the study up to 2 years if they benefit from treatment and can tolerate it. The doctors regularly check the participants' health and note any health problems that could have been caused by the study treatment.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aichi, Nagoya, Japan , Albury, Australia , Amsterdam, Netherlands , Badalona, Spain , Barcelona, Spain , Bengbu, China , Beverly Hills, United States , Bordeaux, France , Brno, Czechia , Brussels, Belgium and 38 more locations